anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine.SUBSTANCE: invention relates to medicine and can be used to diagnose colon cancer by administering a radiopharmaceutical agent (RPA) followed by scintigraphic studies. The patient is injected intravenously at a dose of 500 MBq RPA based on a technetium-99m-labeled glucose derivative. RPA is prepared immediately before use according to laboratory regulations, for which 4 ml of a solution of sodium pertechnetate Na99mTcO4with a volumetric activity of 125 MKb/ml from a generator under aseptic conditions is injected with a syringe into a vial with a reagent. If necessary, the eluate is preliminarily diluted with isotonic sodium chloride solution to the required volumetric activity. The contents of the vial are mixed by shaking and incubated at room temperature for 30 minutes until the reagent is completely dissolved. Further, 40-120 minutes after the intravenous administration of the drug, single-photon emission computed tomography (SPECT) is performed on a two-detector gamma camera in a standard mode. The images obtained during the study are subjected to post-processing processing. During the examination, the patient is placed on the table of the gamma camera in the "supine" position. In the field of view of the gamma camera detectors, the abdominal cavity and the pelvic area should fall. The resulting images are subjected to post-processing computer processing. When visualizing asymmetric areas of RPA hyperfixation in the projection of the colon, a malignant neoplasm is diagnosed.EFFECT: the method provides detection of colon cancer.1 cl, 1 dwg, 1 tbl, 1 ex
TIGLUTIK can cause liver injury. Cases of drug-induced liver injury, some of which were fatal, have been reported in patients taking riluzole. Asymptomatic elevations of hepatic transaminases have also been reported, and in some patients have recurred upon re-challenge with riluzole.

In clinical studies, the incidence of elevations in hepatic transaminases was greater in riluzole-treated patients than placebo-treated patients. The incidence of elevations of ALT above 5 times the upper limit of normal (ULN) was 2% in riluzole-treated patients. Maximum increases in ALT occurred within 3 months after starting riluzole. About 50% and 8% of riluzole-treated patients in pooled controlled efficacy studies (Studies 1 and 2) had at least one elevated ALT level above ULN and above 3 times ULN, respectively [see Clinical Studies (14)]. 

Monitor patients for signs and symptoms of hepatic injury, every month for the first 3 months of treatment, and periodically thereafter. The use of TIGLUTIK is not recommended if patients develop hepatic transaminases levels greater than 5 times the ULN. Discontinue TIGLUTIK if there is evidence of liver dysfunction (e.g., elevated bilirubin). Concomitant use with other hepatotoxic drugs may increase the risk for hepatotoxicity [see Drug Interactions (7.3)] .
This paper is an educationally focused article discussing how transplant infectious diseases (TID) providers balance the risks of accepting or rejecting an organ and have pushed barriers in organ transplantation. We emphasize the role TID providers play in the transplantation process as critical players on the transplant team. We discuss various donor-derived infections that were previously deemed unacceptable for donation due to concerns for transmission. Advances in medical knowledge have changed some of these situations. We discuss the critical role TID providers have in closing the gap between the thousands of patients on organ waitlists and the organ deficit faced each day. We believe TID providers have a unique opportunity to expand the donor pool by increasing education, expanding acceptable organ definitions, and expanding the boundaries of what we can do with potentially transmissible infections in organ transplantation.
High myopia is defined as a refractive error of ≤-6.00D or an axial length greater than 26mm. In recent years, the population of highly myopic individuals has been increasing rapidly. Scholars predict that if no effective interventions are taken, the global incidence rate of myopia is expected to increase from 22.9% in 2000 to 49.8% in 2050, and the visual impairment caused by high myopia will be seven times higher than in 2000 on a global scale. In China, a survey conducted by the National Health Commission in 2018 found that highly myopic students accounted for 21.9% of third-year high school students, indicating that high myopia has become a major public health issue due to its prevalence among younger populations.

In recent years, with the development of ocular imaging technologies such as optical coherence tomography (OCT) and corresponding image analysis techniques, high-resolution, non-invasive, fast and in vivo retinal imaging has become more accessible. This has led to the discovery and exploration of various imaging parameters related to optic disc and macula changes in highly myopic patients. We will conduct a 4 years prospective cohort study in the population of 1000 high myopia and controls which have established in mainly college student population, using the latest OCT-A and SS-OCT to observe the long-term changes of fundus structure combined with visual function in patients with high myopia , and explore biomarkers affecting visual function, so as to provide basis for prevention and control of high myopia and prognosis.
The treatment plan is a two-step design. Day 1 the pt will receive Gemcitabine IV and Day 2 the pt will receive Oxaliplatin IV. This treatment cycle is repeated approximately every 28 days. Subsequent treatment cycle dosages are based on toxicity diaries and lab work results. CT scans are repeated every 2 treatment cycles. Continuation in the study is dependent upon tumor response.
NEW MATERIAL:Polysaccharide TRS having the following properties. [alpha]D<29>= +190.1 (1.8w/v% aqueous solution); molecular weight, 14,000+ or -3,000; sugar constitution, 70.3% glucose, 13.7% rhamnose, and rest part of uronic acid; neutral. USE:An agent to lower the blood triglyceride level and an antiarterioscelerotic agent. PREPARATION:A microbial strain belonging to Streptococcus genus [e.g. Streptococcus faecium (FERM-BP No.296), etc.] is cultured aerobically, e.g. in Rogosa medium, and centrifuged. The obtained microbial cells are suspended in physiological saline water, heated, and disintegrated with ultrasonic radiation to obtain the suspension of disintegrated cells. The suspension is defatted, centrifuged, and treated with a proteolytic enzyme such as pronase. The treated liquid is centrifuged, the supernatant liquid is added with a protein precipitator, etc. to precipitate and remove the protein fraction, and the nucleic acid component and protein component are decomposed and removed by using respective decomposition enzymes.
NEW MATERIAL:Swietenines of formula I (R1 is H, OH or group of formula II; R2 is OH, group of formula Il, III, IV, V, VI, VII, VIII or IX), Swietenolides of formula X and Swietemahonin of formula XI (R3 is H or OH). EXAMPLE:Swietemahonin A. USE:A drug. An active component of platelet coagulation inhibitor. Especially useful for the prevention and remedy for thrombosis such as cerebral infraction, myocardial infarction, cancerous DIC and ischemic diseases and for the prevention of arteriosclerosis and cancer metastasis. PREPARATION:The compounds of formula I, X and XI are produced by (1) extracting cotyledon of Swietenia mahoganii (a plant native to Indonesia) with ether, (2) concentrating the obtained ether solution to form crystalline Swietenine, (3) distilling out ether from mother liquor left after the separation of the crystal to obtain amorphous solid and oily substance and (4) subjecting the oily substance to repeated separation and purification treatments by silica gel chromatography and preparative TLC using various solvents.
Systems and methods for providing surface contrast to display images for micro-surgical applications are disclosed. According to an aspect, an imaging system includes an OCT apparatus configured to capture OCT data of an eye. The OCT image data can include depth-resolved images of reflected light intensity over a period of time. The imaging system also includes a controller configured to determine movement of the eye relative to the OCT imaging field-of-view. The controller may also determine a location within the imaged portion of the eye which tracks with the eye movement. Further, the controller may apply a color gradient to render OCT images of the eye based on a position relative to the determined location of the eye tracking location. The controller may also control a display to display the OCT images with the applied color gradient.
328,347. Wellcome Foundation, Ltd., Smith, S., and Ward, V. J. Feb. 5, 1929. Medicines for internal use.-The active principles of the posterior lobe of the pituitary gland are purified and fractionally separated by employ. ing phenol or cresol, or solutions thereof in alcohol or like solvent as an extracting medium for the glands, or as a solvent for the material salted out from an aqueous extract of the gland by means of ammonium sulphate, or for active protein matter obtained by adding picric, picrolonic or flavianic acid to an aqueous pituitary extract, grinding the precipitate so produced with alcoholic hydrochloric acid and pouring the turbid mixture into acetone to obtain a precipitate. The solution of active materials obtained by any of the above methods is poured into a mixture of ether and light petroleum to obtain a precipitate having relatively great oxytocic and pressor activity. This precipitate is again dissolved in phenol, cresol, or an alcoholic solution thereof and the solution is treated first with ether to give a precipitate having great pressor activity, and then, after saturation with water, with light petroleum to throw down an aqueous layer having substantially only oxytocic activity.
<P>PROBLEM TO BE SOLVED: To provide a method for the topical treatment of nail diseases, e.g. onychomycosis.  <P>SOLUTION: There is provided a method for treating onychomycosis by forming with e.g. pulse laser beam, one or more small orifices traversing the entire nail plate or etching the nail plate, and administering to the nail, a composition containing e.g. an antifungal, e.g. terbinafine. Further, there is provided a device based on laser, e.g. a laser light transmitting device, used in the method, comprising (a) a laser for perforating nail, (b) a supporting means to fix/position the toe or finger to be treated, (c) a pointing laser and (d) optionally an xyz translation stage module, and for forming one or more orifices in one or more nails.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Background: Cellular senescence has emerged as a pivotal focus in cardiovascular research. This study investigates the previously unrecognized role of cellular senescence in septic cardiomyopathy (SCM) and evaluates senomorphic therapy using ruxolitinib (Rux) as a potential treatment option. Methods: We employed lipopolysaccharide (LPS)-induced neonatal rat cardiomyocytes (NRCMs) and two mouse models-LPS-induced and cecal ligation and puncture (CLP)-induced SCM models-to assess Rux's effects. RNA sequencing, western blotting (WB), quantitative polymerase chain reaction (qPCR), immunofluorescence, immunohistochemistry, senescence-associated β-galactosidase (SA-β-gal) assay, and other techniques were utilized to investigate underlying mechanisms. Results: Senescence-associated secretory phenotype (SASP) and cellular senescence markers were markedly elevated in LPS-induced NRCMs and SCM animal models, confirmed by the SA-β-gal assay. Rux treatment attenuated SASP in vitro and in vivo, alongside downregulation of senescence markers. Moreover, Rux-based senomorphic therapy mitigated mitochondrial-mediated apoptosis, improved cardiac function in SCM mice, restored the balance of antioxidant system, and reduced reactive oxygen species (ROS) levels. Rux treatment restored mitochondrial membrane potential, mitigated mitochondrial morphological damage, and upregulated mitochondrial complex-related gene expression, thereby enhancing mitochondrial function. Additionally, Rux treatment ameliorated SCM-induced mitochondrial dynamic dysfunction and endoplasmic reticulum stress. Mechanistically, Rux inhibited JAK2-STAT3 signaling activation both in vitro and in vivo. Notably, low-dose Rux and ABT263 showed comparable efficacy in mitigating SCM. Conclusions: This study highlighted the potential significance of cellular senescence in SCM pathogenesis and suggested Rux-based senomorphic therapy as a promising therapeutic approach for SCM.
The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with slimtube and dome. Hearing aids will be fitted by a certified audiologist according to a gold-standard prescriptive formula (NAL-NL2) using a clinically obtained diagnostic pure tone audiogram. Participants will have access to the smartphone application, but the settings will be limited with only options to change the volume of the hearing aids.
In the fasting group, participants will be asked to fast overnight (at least 10 hours fast) but are allowed to drink water.In the fed state group, participants will start their meal 30 minutes prior to receiving the dose. The meal will consist of high caloric (800-1000 Cal), high fat (\~50% of total calories), with protein, and carbohydrates (\~150 kcal, and \~250 kcal, respectively) content. No food will be administered 4 hours after the dose, and no water will be given 1 hour prior to dose administration and 1 hour after administration. The dose will be given however with a total of 235 mL of water.
Patients receive lutetium texaphyrin IV over 5-20 minutes. A laser delivers 730 nm of light to the cervix for 4, 8, or 16 minutes. Patients undergo LEEP at 4, 8, or 12 hours after exposure of the cervix to the light source.
Infectious medicine faces a variety of challenges, such as the increase in antibiotic resistance and the emergence and spread of infectious diseases fueled by climate change and globalization. Precision medicine can provide solutions to many of these challenges. Since an untargeted request for diagnostic tests can lead to test results without clinical relevance, which can increase the use of non-indicated antibiotics, the principle aimed at is: targeted diagnostics (the right test) and consideration of patient characteristics (the right person) to optimize management (the right action). At the same time, one must always decide whether empirical therapy must be immediately initiated, even if the results of the initiated diagnostics are not yet available. In addition, many new diagnostics as well as therapies have recently been developed for the rapid detection and more specific treatment of bacterial infections. Molecular genetic methods, which offer more rapid results than classical bacterial cultures, are gaining ground as new diagnostics. New therapeutics such as bacteriophages, antibodies or antibacterial peptides allow increasingly precise treatment of certain bacterial infections. Precision medicine will also play an increasingly important role in infectious medicine in the future.
Participants in the control arm will be provided facilitated referral to community HCV providers by an on-site care coordinator already facilitating care at the community site. HCV RNA negative participants will be called to inform them of these results, and then followed separately. HCV RNA positive participants will be asked during the semi-structured interviews as at 12, 24, 36 and 48 week if they engaged in HCV treatment to assess whether their HCV referral has been filled, and to record their current HCV treatment status. They will also receive repeat HCV RNA testing at week 12, 24, and 48. Participants that have started treatment will be asked to sign consent for release of medical records pertaining to HCV-related laboratory testing to determine achievement of treatment response.
The thumb carpometacarpal (CMC) joint is one of the most likely joints to develop osteoarthritis (OA). If conservative treatments fail to alleviate symptoms, surgery may be pursued. Kinematic outcomes of CMC surgery techniques have been described, but current tools have limitations in capturing motion abilities. The goals of this study were (1) develop a new and robust set of kinematic outcome measures, and apply them to (2) a cohort of younger and older control individuals without CMC OA to determine age and sex-related changes, and (3) a cohort of participants with CMC OA before, 3 months, and 6 months after undergoing thumb ligament reconstruction with tendon interposition surgery to detect the impacts of surgery. 52 (26 males, 26 females) control and 18 (3 males, 15 females) surgical participants were tested. Kinematics were investigated using motion capture by mapping the three-dimensional motion space of the whole thumb, and two-dimensional motion boundaries of the metacarpal (MC) and proximal phalange (PP). Visual analog pain score was recorded. Older control participants had shifted regions of motion compared to younger participants (p ≤ 0.027), suggesting asymptomatic CMC wear. Control females had 31% more metacarpophalangeal (MCP) motion than control males (p = 0.013), which could alter loading paths through the CMC joint and increase OA risk. Pain at 6 months postsurgery was 72% less than presurgery (p < 0.001), but motion abilities were 20-28% less than presurgery (p ≤ 0.074) and 24-40% less than control participants (p ≤ 0.066). These techniques have the possibility of identifying presymptomatic motion changes, including those at the metacarpophalangeal joint in CMC OA progression.
Diagnostic errors are a relevant health-care problem. As medical history taking is usually the first step in a patient's assessment its quality is most likely a first and important barrier against diagnostic errors. There are, however, only limited data on the association of the quality of medical history taking and diagnostic accuracy.This prospective randomized simulator-based single-blind trial aimed to investigate the effects of initial cues and history taking skills on diagnostic accuracy. 198 medical students (135 females) were given the task to assess a patient presenting with simulated acute pulmonary embolism. Participants were randomized to six versions of the scenario differing only in the initial cues, i.e. in the reply of the patient to the initial question about the reason for his visit. In three of six versions, initial cues were restricted to thoracic symptoms (chest pain, dyspnoea, or combination of both). In the remaining three versions, initial cues consisted of thoracic and extra-thoracic (leg pain, immobilization) symptoms. The primary outcome was diagnostic accuracy. The mannequin was equipped with a speaker in its head that broadcasts the voice of a remote operator (experienced physician) allowing verbal interaction of the participants with the "patient". The "patient" did not speak unless asked and responded to all participants' questions during history taking according to a pre-defined checklist.
Technologies are described for a formulation and production of a formulation. The methods may comprise depositing a non-steroidal anti-inflammatory drug (NSAID) compound into a chamber. The methods may comprise depositing a muscle relaxant into the chamber. The methods may comprise depositing a calcium channel blocker into the chamber. The methods may comprise depositing a general anesthetic into the chamber. The methods may comprise depositing a local anesthetic into the chamber. The methods may comprise milling and mixing the NSAID compound, the muscle relaxant, the calcium channel blocker, the general anesthetic, and the local anesthetic into a powder. The methods may comprise adding a solvent with the powder. The methods may comprise mixing the solvent with the powder to form a solution. The methods may comprise adding a base cream to the solution. The methods may comprise mixing the base cream and the solution to form the formulation.
If the caregiver is assigned to the Pep-Pal intervention condition, the RA will provide access to the mobilized website (passcode) through an email. Caregivers will be instructed to watch each session at least once. It will be recommended that caregivers watch one to two new sessions per week so that they can have enough time to practice the skills between sessions. In addition, they will be told that they can go back and watch the sessions for review as many times as they like. Full participation will be defined as watching at least 7/9 sessions (75% of program) based on previous criteria for similar intervention completion in a prior trial with advanced cancer patients.
PURPOSE: Textbook outcome is a comprehensive measure used to assess surgical quality and is increasingly being recognized as a valuable evaluation tool. Delta-shaped anastomosis (DA), an intracorporeal gastroduodenostomy, is a viable option for minimally invasive distal gastrectomy in patients with gastric cancer. This study aims to evaluate the surgical outcomes and calculate the textbook outcome of DA.
MATERIALS AND METHODS: In this retrospective study, the records of 4,902 patients who underwent minimally invasive distal gastrectomy for DA between 2009 and 2020 were reviewed. The data were categorized into three phases to analyze the trends over time. Surgical outcomes, including the operation time, length of post-operative hospital stay, and complication rates, were assessed, and the textbook outcome was calculated.
RESULTS: Among 4,505 patients, the textbook outcome is achieved in 3,736 (82.9%). Post-operative complications affect the textbook outcome the most significantly (91.9%). The highest textbook outcome is achieved in phase 2 (85.0%), which surpasses the rates of in phase 1 (81.7%) and phase 3 (82.3%). The post-operative complication rate within 30 d after surgery is 8.7%, and the rate of major complications exceeding the Clavien-Dindo classification grade 3 is 2.4%.
CONCLUSIONS: Based on the outcomes of a large dataset, DA can be considered safe and feasible for gastric cancer.
The present invention relates to a Chinese medicine ointment for revitalizing the nerves, which is used for treating neurogenic diseases, and a production method for the ointment. The present invention can effectively solve the problems of the treatment of neurogenic chronic diseases, and the ointment of the present invention is prepared from twelve cany Chinese medicines such as tripterygium wilfordii, etc. and long-noded pit viper, garter snake, scorpion, centipede, leech, pangolin, minium, musk, camphor, borneol and sesame oil. The present invention has the production method that the twelve cany Chinese medicines such as tripterygium wilfordii, etc. and the long-noded pit viper, the garter snake, the scorpion, the centipede, the leech and the pangolin are immersed in the sesame oil at a temperature of 5 to 40 DEG C for 5 to 10 days, are put in a pan to be fried, are filtered to obtain medicinal oil, are refined by fire, and then are put away from the fire by adding the minium; after the temperature drops, the musk, the camphor and the borneol are added and evenly mixed, and fire toxin is eliminated by cold water so as to spread the Chinese medicines over a cloth surface, a paper surface, etc. The present invention has the advantages of abundant medicinal material, low price, low cost, convenient application, security, fine curative effect, simple method, easy production, easy decoction, easy popularization, easy application and great social and economic benefit.